FDG-PET/CT in oncology

被引：51

作者：

Krause, B. J. ^{[1
]}

Beyer, T. ^{[2
]}

Bockisch, A. ^{[2
]}

Delbeke, D. ^{[3
]}

Kotzerke, J. ^{[4
]}

Minkov, V. ^{[5
]}

Reiser, M. ^{[6
]}

Willich, N. ^{[7
]}

机构：

[1] Tech Univ Munich, Klinikum Rechts Isar, Nukl Med Klin & Poliklin, D-81675 Munich, Germany

[2] Univ Klinikum Essen, Klin Nukl Med, Essen, Germany

[3] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[4] Univ Klinikum Dresden, Klin & Poliklin Nukl Med, Dresden, Germany

[5] Bundesamt Strahlenschutz, Salzgitter, Germany

[6] Univ Munich, Inst Klin Radiol, D-80539 Munich, Germany

[7] Univ Klinikum Munster, Klin & Poliklin Strahlentherapie Radioonkol, Munster, Germany

来源：

NUKLEARMEDIZIN-NUCLEAR MEDICINE | 2007年 / 46卷 / 06期

关键词：

guideline; FDG; PET/CT; oncology;

D O I：

10.3413/nukmed-282

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

FDG-PET/CT examinations combine metabolic and morphologic imaging within an integrated procedure. Over the post decade PET/CT imaging has gained wide clinical acceptance in the field of oncology. This FDG-PET/CT guideline focuses on indications, data acquisition and processing as well as documentation of FDG-PET/CT examinations in oncologic patients within a clinical and social context specific to Germany. Background information and definitions are followed by examples of clinical and research applications of FDG-PET/CT. Furthermore, protocols for CT scanning (low dose and contrast-enhanced CT) and PET emission imaging are discussed. Documentation and reporting of examinations are specified. Image interpretation criteria and sources of errors are discussed. Quality control for FOG and PET/CT-systems, qualification requirements of personnel as well as legal aspects are presented.

引用

页码：291 / 301

页数：11

共 50 条

[1] Contrast-media-induced nephrotoxicity - Clinic and prevention [J].

Adolph, E ;

Chatterjee, T ;

Ince, H ;

Eckard, H ;

Rehders, T ;

Kische, S ;

Drawert, S ;

Petzsch, M ;

Nienaber, CA .

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2005, 130 (42) :2391-2396

[2]

Allen-Auerbach M, 2006, J NUCL MED, V47, P298

[3] Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology [J].

Antoch, G ;

Vogt, FM ;

Freudenberg, LS ;

Nazaradeh, F ;

Goehde, SC ;

Barkhausen, J ;

Dahmen, G ;

Bockisch, A ;

Debatin, JF ;

Ruehm, SG .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (24) :3199-3206

[4]

Antoch G, 2004, J NUCL MED, V45, p56S

[5]

Antoch G, 2002, J NUCL MED, V43, P1339

[6]

*ASRT, 2002, J NUCL MED TECHNOL, V30, P201

[7] PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients [J].

Berthelsen, AK ;

Holm, S ;

Loft, A ;

Klausen, TL ;

Andersen, F ;

Hojgaard, L .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (10) :1167-1175

[8] Respiration artifacts in whole-body 18F-FDG PET/CT studies with combined PET/CT tomographs employing spiral CT technology with 1 to 16 detector rows [J].

Beyer, T ;

Rosenbaum, S ;

Veit, P ;

Stattaus, J ;

Müller, SP ;

DiFilippo, FP ;

Schöder, H ;

Mawlawi, O ;

Roberts, F ;

Bockisch, A ;

Kühl, H .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (12) :1429-1439

[9]

Beyer T, 2000, J NUCL MED, V41, P1369

[10] Putting 'clear' into nuclear medicine: a decade of PET/CT development [J].

Beyer, Thomas ;

Townsend, David W. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 (08) :857-861

← 1 2 3 4 5 →